Providing the first overview of Asia’s emerging biosciences landscape, this timely and important collection brings together ethnographic case studies on biotech endeavors such as genetically modified foods in China, clinical trials in India, blood collection in Singapore and China, and stem-cell research in Singapore, South Korea, and Taiwan. While biotech policies and projects vary by country, the contributors identify a significant trend toward state entrepreneurialism in biotechnology, and they highlight the ways that political thinking and ethical reasoning are converging around the biosciences. As ascendant nations in a region of postcolonial emergence, with an “uncanny surplus” in population and pandemics, Asian countries treat their populations as sources of opportunity and risk. Biotech enterprises are allied to efforts to overcome past humiliations and restore national identity and political ambition, and they are legitimized as solutions to national anxieties about food supplies, diseases, epidemics, and unknown biological crises in the future. Biotechnological responses to perceived risks stir deep feelings about shared fate, and they crystallize new ethical configurations, often re-inscribing traditional beliefs about ethnicity, nation, and race. As many of the essays in this collection illustrate, state involvement in biotech initiatives is driving the emergence of “biosovereignty,” an increasing pressure for state control over biological resources, commercial health products, corporate behavior, and genetic based-identities. Asian Biotech offers much-needed analysis of the interplay among biotechnologies, economic growth, biosecurity, and ethical practices in Asia.

Contributors
Vincanne Adams
Nancy N. Chen
Stefan Ecks
Kathleen Erwin
Phuoc V. Le
Jennifer Liu
Aihwa Ong
Margaret Sleeboom-Faulkner
Kaushik Sunder Rajan
Wen-Ching Sung
Charis Thompson
Ara Wilson

Biocapital is a major theoretical contribution to science studies and political economy. Grounding his analysis in a multi-sited ethnography of genomic research and drug development marketplaces in the United States and India, Kaushik Sunder Rajan argues that contemporary biotechnologies such as genomics can only be understood in relation to the economic markets within which they emerge. Sunder Rajan conducted fieldwork in biotechnology labs and in small start-up companies in the United States (mostly in the San Francisco Bay area) and India (mainly in New Delhi, Hyderabad, and Bombay) over a five-year period spanning 1999 to 2004. He draws on his research with scientists, entrepreneurs, venture capitalists, and policymakers to compare drug development in the two countries, examining the practices and goals of research, the financing mechanisms, the relevant government regulations, and the hype and marketing surrounding promising new technologies. In the process, he illuminates the global flow of ideas, information, capital, and people connected to biotech initiatives.

Sunder Rajan’s ethnography informs his theoretically sophisticated inquiry into how the contemporary world is shaped by the marriage of biotechnology and market forces, by what he calls technoscientific capitalism. Bringing Marxian theories of value into conversation with Foucaultian notions of biopolitics, he traces how the life sciences came to be significant producers of both economic and epistemic value in the late twentieth century and early twenty-first.

Lively Capital is an urgent and important collection of essays addressing the reconfigured relations between the life sciences and the market. Exploring the ground where social and cultural anthropology intersect with science and technology studies, prominent scholars investigate the relationship of biotechnology to ethics, governance, and markets, as well as the new legal, social, cultural, and institutional mechanisms emerging to regulate biotechnology. The contributors examine genomics, pharmaceutical marketing, intellectual property, environmental science, clinical trials, patient advocacy, and other such matters as they are playing out in North and South America, Europe, Africa, and Asia. Lively Capital is not only about the commercialization of the life sciences, but their institutional histories, epistemic formations, and systems of valuation. It is also about the lively affects—the emotions and desires—involved when technologies and research impinge on experiences of embodiment, kinship, identity, disability, citizenship, accumulation, and dispossession. At stake in the commodification of the life sciences are opportunities to intervene in and adjudicate matters of health, life, and death.

Contributors. Timothy Choy, Joseph Dumit, Michael M. J. Fischer, Kim Fortun, Mike Fortun, Donna Haraway, Sheila Jasanoff, Wen-Hua Kuo, Andrew Lakoff, Kristin Peterson, Chloe Silverman, Elta Smith, Kaushik Sunder Rajan, Travis J. Tanner

Continuing his pioneering theoretical explorations into the relationships among biosciences, the market, and political economy, Kaushik Sunder Rajan introduces the concept of pharmocracy to explain the structure and operation of the global hegemony of the multinational pharmaceutical industry. He reveals pharmocracy's logic in two case studies from contemporary India: the controversial introduction of an HPV vaccine in 2010, and the Indian Patent Office's denial of a patent for an anticancer drug in 2006 and ensuing legal battles. In each instance health was appropriated by capital and transformed from an embodied state of well-being into an abstract category made subject to capital's interests. These cases demonstrate the precarious situation in which pharmocracy places democracy, as India's accommodation of global pharmaceutical regulatory frameworks pits the interests of its citizens against those of international capital. Sunder Rajan's insights into this dynamic make clear the high stakes of pharmocracy's intersection with health, politics, and democracy.